AU2020282748A1 - Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith - Google Patents

Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith Download PDF

Info

Publication number
AU2020282748A1
AU2020282748A1 AU2020282748A AU2020282748A AU2020282748A1 AU 2020282748 A1 AU2020282748 A1 AU 2020282748A1 AU 2020282748 A AU2020282748 A AU 2020282748A AU 2020282748 A AU2020282748 A AU 2020282748A AU 2020282748 A1 AU2020282748 A1 AU 2020282748A1
Authority
AU
Australia
Prior art keywords
compound
substituted
unsubstituted
alkyl
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020282748A
Other languages
English (en)
Inventor
Frans BACULI
Matthew D. Correa
Joshua Hansen
Laurie A. LEBRUN
Chin-Chun Lu
Gang Lu
Mark A. Nagy
Katherine NORTHCOTE
Sophie PENG
Sophie Perrin-Ninkovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AU2020282748A1 publication Critical patent/AU2020282748A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
AU2020282748A 2019-05-31 2020-05-29 Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith Abandoned AU2020282748A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855619P 2019-05-31 2019-05-31
US62/855,619 2019-05-31
PCT/US2020/035043 WO2020243379A1 (en) 2019-05-31 2020-05-29 Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
AU2020282748A1 true AU2020282748A1 (en) 2021-12-09

Family

ID=73551319

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020282748A Abandoned AU2020282748A1 (en) 2019-05-31 2020-05-29 Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith

Country Status (19)

Country Link
US (2) US11306101B2 (cg-RX-API-DMAC7.html)
EP (1) EP3976595B1 (cg-RX-API-DMAC7.html)
JP (2) JP7496838B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250078628A (cg-RX-API-DMAC7.html)
CN (4) CN118724867A (cg-RX-API-DMAC7.html)
AR (1) AR119057A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020282748A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022758A2 (cg-RX-API-DMAC7.html)
CA (1) CA3136753A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003134A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021015624A2 (cg-RX-API-DMAC7.html)
IL (1) IL288278B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021014350A (cg-RX-API-DMAC7.html)
MY (1) MY208545A (cg-RX-API-DMAC7.html)
PE (1) PE20220569A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112872YA (cg-RX-API-DMAC7.html)
TW (2) TW202523657A (cg-RX-API-DMAC7.html)
WO (1) WO2020243379A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202109003B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119057A1 (es) 2019-05-31 2021-11-17 Celgene Corp Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
JP7863100B2 (ja) * 2020-10-14 2026-05-20 シーフォー セラピューティクス, インコーポレイテッド Ikzf2又はikzf4を分解する三環式リガンド
CN112679421A (zh) * 2021-01-04 2021-04-20 都创(上海)医药科技股份有限公司 一种(r)-3-氯吡啶基-2-三氟乙胺盐酸盐的合成方法
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
JP2024517808A (ja) * 2021-05-06 2024-04-23 セルジーン コーポレーション N-((r)-1-(3-クロロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-((s)-2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミドによる治療方法
AU2022289605B2 (en) * 2021-06-08 2024-12-19 Hangzhou Glubio Pharmaceutical Co., Ltd. Isoindolinone compounds, and uses thereof
CN115504963A (zh) * 2021-06-22 2022-12-23 苏州开拓药业股份有限公司 一种c-Myc蛋白降解剂
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
WO2023244815A1 (en) * 2022-06-16 2023-12-21 Monte Rosa Therapeutics, Inc. Molecular glue degraders and methods of using the same
EP4540238A1 (en) * 2022-06-16 2025-04-23 Monte Rosa Therapeutics AG Molecular glue degraders and methods of using the same
US20260055077A1 (en) * 2022-08-01 2026-02-26 Suzhou Kintor Pharmaceuticals, Inc. Protein degradation agent
CN120344512A (zh) * 2022-12-07 2025-07-18 杭州格博生物医药有限公司 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
US20260199316A1 (en) * 2022-12-07 2026-07-16 Hangzhou Glubio Pharmaceutical Co., Ltd Solid dispersion, preparation method therefor, and use thereof
PL249026B1 (pl) * 2022-12-09 2026-02-23 Univ Mikolaja Kopernika W Toruniu Pochodna azetydyno-2,4-dionu, sposób jej otrzymywania i zastosowanie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
CA2822094C (en) * 2005-08-31 2015-10-27 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
CN101578277A (zh) * 2006-08-30 2009-11-11 细胞基因公司 5-取代的异二氢吲哚化合物
AU2007290407A1 (en) 2006-08-30 2008-03-06 Celgene Corporation 5-substituted isoindoline compounds
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CA2994969A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
AR119057A1 (es) 2019-05-31 2021-11-17 Celgene Corp Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos

Also Published As

Publication number Publication date
KR20250078628A (ko) 2025-06-02
KR20220016167A (ko) 2022-02-08
PE20220569A1 (es) 2022-04-20
IL288278A (en) 2022-01-01
US20220213115A1 (en) 2022-07-07
US11306101B2 (en) 2022-04-19
JP2022534979A (ja) 2022-08-04
US20200377512A1 (en) 2020-12-03
CA3136753A1 (en) 2020-12-03
CN114957212A (zh) 2022-08-30
IL288278B2 (en) 2025-09-01
KR102913106B1 (ko) 2026-01-19
TW202523657A (zh) 2025-06-16
CO2021015624A2 (es) 2022-02-28
MX2021014350A (es) 2022-02-21
US12486281B2 (en) 2025-12-02
TW202110819A (zh) 2021-03-16
CN118724867A (zh) 2024-10-01
EP3976595A4 (en) 2023-01-04
JP7496838B2 (ja) 2024-06-07
CN114269729B (zh) 2025-01-17
AR119057A1 (es) 2021-11-17
CL2021003134A1 (es) 2022-07-01
IL288278B1 (en) 2025-05-01
ZA202109003B (en) 2025-01-29
MY208545A (en) 2025-05-14
CN114957212B (zh) 2024-05-24
EP3976595A1 (en) 2022-04-06
CN114269729A (zh) 2022-04-01
CN119930578A (zh) 2025-05-06
BR112021022758A2 (pt) 2022-03-22
WO2020243379A1 (en) 2020-12-03
JP2024123001A (ja) 2024-09-10
TWI851729B (zh) 2024-08-11
SG11202112872YA (en) 2021-12-30
EP3976595B1 (en) 2026-07-29

Similar Documents

Publication Publication Date Title
US12486281B2 (en) Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
JP7745679B2 (ja) 置換された4-アミノイソインドリン-1,3-ジオン化合物、及びリンパ腫の治療のためのそれらの使用
KR102866144B1 (ko) 치환된 3-((3-아미노페닐)아미노)피페리딘-2,6-디온 화합물, 이의 조성물, 및 이를 사용한 치료 방법
KR102851010B1 (ko) 포스파티딜이노시톨 3-키나제 저해제
KR20210118828A (ko) 치환된 3-((3-아미노페닐)아미노)피페리딘-2,6-디온 화합물, 이의 조성물, 및 이를 사용한 치료 방법
JP2025537273A (ja) 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物との組み合わせ療法
US20240208937A1 (en) Compounds and Their Use for Treatment of Hemoglobinopathies
EA050422B1 (ru) Замещенные 1-оксоизоиндолин-5-карбоксамидные соединения, содержащие их композиции и способы лечения с их помощью
EA046753B1 (ru) Замещенные 1-оксоизоиндолин-5-карбоксамидные соединения, содержащие их композиции и способы лечения с их помощью
US20250100995A1 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40102392A (en) Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
HK40049471A (en) Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
HK40049471B (en) Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted